Sign in Subscribe
Cancer research

Real-World Data on Triplet Therapy for Prostate Cancer Shows Promise, but Limited Efficacy

Strategic Insights

— 1 min read

A study published in the Journal of Nippon Medical School examined the clinical outcomes of triplet therapy in patients with metastatic castration-sensitive prostate cancer (mCSPC) at Nippon Medical School Hospital in Japan. The research aimed to evaluate the efficacy and safety of the treatment, which consisted of androgen deprivation therapy, docetaxel, and darolutamide.

Researchers retrospectively analyzed the data of 14 patients with mCSPC who received triplet therapy between January 2023 and June 2024. The results showed that all patients achieved a significant reduction in prostate-specific antigen (PSA) levels, with 13 patients experiencing a reduction of 99%. However, grade 3 or higher adverse events (AEs) occurred in 10 patients, and one patient permanently discontinued treatment due to AEs.

Key Takeaways:

  • The study evaluated the clinical outcomes of triplet therapy in 14 patients with metastatic castration-sensitive prostate cancer (mCSPC) at Nippon Medical School Hospital in Japan.
  • All patients achieved a significant reduction in prostate-specific antigen (PSA) levels, with 13 patients experiencing a reduction of 99%.
  • Grade 3 or higher adverse events (AEs) occurred in 10 patients, and one patient permanently discontinued treatment due to AEs.
  • The median follow-up period was 7.9 months, and biochemical progression was observed in 2 patients and radiological progression in 2 patients.
  • Subsequent therapies were selected based on each patient's clinicopathological and genetic characteristics, with considerable variability in treatment approaches following progression.
  • The study highlighted the need for close monitoring and individualized treatment in patients with mCSPC receiving triplet therapy.

Statistics:

  • 14 patients with mCSPC received triplet therapy at Nippon Medical School Hospital.
  • 13 patients (93%) achieved reductions in PSA levels of 99%.
  • 10 patients (71%) experienced grade 3 or higher AEs.
  • 1 patient (7%) permanently discontinued treatment due to AEs.
  • Biochemical progression was observed in 2 patients (14%).
  • Radiological progression was observed in 2 patients (14%).

Sources:

  • Real-world Experience With Triplet Therapy for High-volume Metastatic Castration-sensitive Prostate Cancer: a Retrospective Cohort Study From a Japanese Academic Hospital. Journal of Nippon Medical School, 2025;92(2):204-215.
  • NewsRx. New Prostate Cancer Study Findings Reported from Nippon Medical School (Real-world Experience With Triplet Therapy for High-volume Metastatic Castration-sensitive Prostate Cancer: a Retrospective Cohort Study From a Japanese Academic Hospital). Health & Medicine Week. June 20, 2025; p 2940.

Read more